

Liquid Biopsy
Cancer Screening and Detection

epigenomics

Q3 2018 Earnings Release



Safe harbor statement

This communication contains certain forward-looking statements, including, without limitation, statements containing the words “expects”, “future”, “potential” and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Recent operational highlights

THIRD QUARTER PERFORMANCE IN LINE WITH PREVIOUS QUARTERS; FY 2018 OUTLOOK ADJUSTED

CAPITAL RAISE SUCCESSFULLY COMPLETED; GROSS PROCEEDS OF EUR 22.3 MILLION

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PUBLISH FINAL RATE OF $192 FOR SEPTIN 9 EPC TEST.

U.S. CONGRESS URGES CMS TO CONSIDER COVERAGE OF BLOOD TESTS FOR COLORECTAL CANCER SCREENING

HCCBloodTest™

TO AID IN DETECTING LIVER CANCER AMONG PATIENTS WITH CIRRHOSIS

Q3 2018 - Key financials

EURm	Q3-2018	Q3-2017	Change in %
Revenue	0.5	0.3	57%
Adj. EBITDA*	(2.6)	(2.0)	28%
Net result	(3.0)	(1.1)	>100%
Cash consumption	2.7	2.7	1%

*EBITDA before share-based payment expenses

- Increase in revenue driven by higher product sales (+73%) for Epi proColon
- Decline in adjusted EBITDA mainly due to higher R&D expenses, partially offset by growth in gross profit
- Net result in line with EBITDA; Q3 2017 impacted by non-recurring positive effect
- Cash consumption in line with Q3 of previous year

Liquid assets

EURm	Sep 30, 2018	Dec 31, 2017
Liquid assets*	6.6	13.7

*cash and cash equivalents incl. marketable securities

- Gross proceeds of EUR 22.3m from recent capital increase significantly improve financial position
- Current funds sufficient to continue business operations well into 2020
- Approximately 12 million new shares placed at a price of EUR 1.86
- Subscription rate of existing shareholders at 67%
- Placement of remaining shares significantly oversubscribed
- All shares of the private placement were allocated to multiple new institutional investors in the U.S.A, including healthcare funds

Financial outlook 2018 adjusted

Within range of EUR 1.5m to 2.5m

Within range of EUR -11.0m to -13.0m

In line with EBITDA* guidance

*EBITDA before share-based payment expenses

Medicare Reimbursement to be Key Milestone

Coverage

- Legislation
- National Coverage Decision (NCD)

Rate

- Final Gapfill Price Set at $192

Key Reimbursement Coverage Milestones

Legislation

- [x] Bi-partisan House Bill Introduced
- [x] Bi-partisan Senate Bill Introduced
- [x] “Blood Test” Coverage Urged in 2019 Health and Human Services Appropriations Bill
- [ ] Congressional Budget Office (CBO) Score (expected within 2018)
- [ ] “Blood Test” Bill Move to Vote or Incorporated into Larger Bill for Vote

National Coverage Decision (NCD)

- [x] FDA- Approval
- [x] Initiate Microsimulation Model
- [x] CMS sets final Price => $192
- [ ] Complete & Publish Model (Q2, 2019)
- [ ] Clinical Guideline Inclusion (2019)

High Value Screening Test



Clinical Lab Fee Schedule 2018 CMS.gov
2018 Preliminary Gapfill rates 2018 CMS.gov

HCC BloodTest™ for Liver Cancer Detection

Global Liver Cancer Market: > $3.5 Billion

- In China, HCC is the second most frequent cancer and the leading cause of cancer-related deaths
  - A total of 466,000 new cases of HCC in 2015 and an estimated 422,100 deaths
- In the US over 40,000 people will be diagnosed with HCC in 2018
  - Close to an estimated 3 million people may suffer from Cirrhosis in the US
- Liver cancer is responsible for around 47,000 deaths per year in the EU
  - An estimated 3 million people may suffer from Cirrhosis in the EU, including those who are asymptomatic

Next Steps:

- CE Mark in EU
  - Sponsor additional Studies in Europe
- Cross-sectional U.S. Study Focused on Early Stage Disease
- Pre-submission Meeting with FDA
- Initiation of Longitudinal Prospective Clinical Trial in U.S.

Significant 2018 Goals Achieved

Operational

- CMS pricing ✓
- CE mark liver cancer test ✓
- Coverage

Financial

- Near- to mid-term funding ✓



Analyst & Investor Conference Call

Third Quarter 2018 Financial Results

Q&A-Session